Ilyang Pharmaceutical Co., Ltd announced that it has received KRW 30 billion in funding from Hana Daetoo Securities Co., Ltd., Investment Arm, Hanyang Securities Co. Ltd., Investment Arm, Hungkuk Life Insurance Co., Ltd., Korea Securities Finance Corporation, Investment Arm, KTB Investment & Securities Co.,Ltd., and SBI Savings Bank Inc., Investment Arm.
June 13, 2014 at 05:00 am
Share
Ilyang Pharmaceutical Co., Ltd (KOSE:A007570) announced a private placement of round 79 unregistered coupon unsecured private convertible bonds for gross proceeds of KRW 30,000,000,000 on June 12, 2014. The bonds will carry yield to maturity of 1% and 0% coupon rate. The bonds will mature on June 13, 2019. The conversion rate of the bonds will be 100%. The bonds will be convertible into the registered common shares at KRW 27,350 per share. The conversion period will start on June 13, 2015 and end on June 5, 2019. The subscription date and payment date for the transaction is June 13, 2014. The transaction will include participation from new investors, KTB Private Equity for KRW 15,500,000,000, Hanyang Securities Co. Ltd., Investment Arm for KRW 3,000,000,000, Hungkuk Life Insurance Co., Ltd. for KRW 4,000,000,000, SBI Savings Bank Inc., Investment Arm for KRW 3,000,000,000, Hana Daetoo Securities Co., Ltd., Investment Arm for KRW 2,000,000,000, and Korea Securities Finance Corporation, Investment Arm for KRW 1,500,000,000 as a broker of Golden bridge with high yield private security investment trust no. 1 and for KRW 1,000,000,000 as a broker of LS with separation taxation and high yield private security investment trust no. 1. The transaction has been approved by the board of directors of the company.
On June 13, 2014, Ilyang Pharmaceutical Co., Ltd closed the transaction.
Ilyang Pharmaceutical Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including prostatitis agents, anti-inflammatory drugs, diabetic agents, gastritis agents, and others. The Company also produces products including nourishing tonics and health supplements, among others.
Ilyang Pharmaceutical Co., Ltd announced that it has received KRW 30 billion in funding from Hana Daetoo Securities Co., Ltd., Investment Arm, Hanyang Securities Co. Ltd., Investment Arm, Hungkuk Life Insurance Co., Ltd., Korea Securities Finance Corporation, Investment Arm, KTB Investment & Securities Co.,Ltd., and SBI Savings Bank Inc., Investment Arm.